According to a new announcement, AL-S Pharma’s AP-101, a monoclonal antibody targeting misfolded SOD1, met its primary safety and tolerability end poi...

WATCH TIME: 3 minutes "The migraine field is unique in that even without a clear biomarker, we’ve managed to build a growing therapeutic arsenal. With...

WATCH TIME: 3 minutes | Captions are auto-generated and may contain errors. Lennox-Gastaut syndrome (LGS) is a rare epilepsy syndrome that typically b...

In a recently published study of patients with relapsing-remitting multiple sclerosis (RRMS), data showed that the seroconversion rate for John Cunnin...

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from ne...

Episode 149 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming servi...

In a recent company announcement, Bio-Thera Solutions has decided to close patient enrollment for its pivotal phase 2/3 trial (NCT06044350) of BAT4406...

WATCH TIME: 5 minutes | Captions are auto-generated and may contain errors. "It was an incredible meeting at the Alzheimer's Association International...

WATCH TIME: 4 minutes "For the first time, we have a regulatory trial that includes the full spectrum of developmental and epileptic encephalopathies,...

Newly published findings from the randomized controlled POWER@MS1 trial (NCT03968172) assessing Levidex showed that the cognitive behavioral therapy-b...